Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
Chronic Lymphocytic Leukemia|Richter Syndrome
DRUG: Umbralisib|BIOLOGICAL: ublituximab|BIOLOGICAL: TG-1501
Determine Acceptable Adverse Events That Are Related to Treatment, To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities, 6 months of therapy
Overall Response Rate, The overall response rate (ORR) in patients with CLL and Richter's Transformation treated with Ublituximab in combination with Umbralisib and Targeted Immunotherapy, Up to 1 year
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.